Bristol-Myers Squibb Co.

BMY

Bristol-Myers Squibb Co. is a global pharmaceutical company focused on discovering, developing, and delivering innovative medicines in areas such as oncology, immunology, cardiovascular, and neuroscience. Founded in 1858, it has a long history of advancing health through its diverse portfolio of prescription therapies.

$53.06 0.00 (0.00%)
Dividend Yield 4.69%
Payout Frequency Quarterly

Dividend History

🎉 Upcoming Dividend

Investors can expect a dividend payout of $0.63 per share, scheduled to be distributed in 27 days on February 2, 2026

Pay DateAmountEx-DateRecord Date
February 2, 2026$0.632026-01-022026-01-02
November 3, 2025$0.622025-10-032025-10-03
August 1, 2025$0.622025-07-032025-07-03
May 1, 2025$0.622025-04-042025-04-04
February 3, 2025$0.622025-01-032025-01-03

Dividends Summary

Company News

1 Top ETF I Plan to Load Up on in 2026
The Motley Fool • Matt Dilallo • January 2, 2026

Matt DiLallo recommends loading up on the Schwab U.S. Dividend Equity ETF (SCHD) in 2026. The ETF tracks the top 100 high-yielding dividend stocks with strong dividend growth histories. After underperforming in 2025 (up only 1% vs S&P 500's 17%), SCHD now trades at a more attractive valuation (17x earnings vs S&P 500's 25x) with a 3.7% dividend y...

Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider
GlobeNewswire Inc. • Sns Insider • December 14, 2025

The global immuno-oncology clinical trials market is expected to grow from USD 8.30 billion in 2023 to USD 23.63 billion by 2032, driven by rising cancer incidence, significant R&D investments, and advancements in immunotherapies like checkpoint inhibitors and CAR-T cell therapies.

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options
Benzinga • Vandana Singh • December 9, 2025

BioNTech and Bristol Myers Squibb reported promising interim data for pumitamig, a drug combination showing encouraging anti-tumor responses for triple-negative breast cancer patients with limited treatment options.

The Market’s a Ripoff Right Now, but These 4 High Yielders Aren’t
Investing.com • Brett Owens • November 14, 2025

The article highlights four high-yielding dividend stocks trading at attractive valuations amid market uncertainty, focusing on packaging and pharmaceutical companies with strong dividend histories and low valuation metrics.

What Lies in Store for Healthcare ETFs in Q2 Earnings? - Zacks Investment Research
Zacks Investment Research • Zacks Investment Research • July 24, 2024

The healthcare sector has gained momentum recently, with investors rushing to buy beaten-down stocks. The performance of major healthcare ETFs like XLV, VHT, IYH, and FHLC will depend on the upcoming earnings releases of big names like Pfizer, Merck, Amgen, AbbVie, Bristol Myers Squibb, and Eli Lilly.

Related Companies